A photo of Benjamin Mizukawa.

Research Director, Pediatric Cancer Avatar Program

Assistant Professor, UC Department of Pediatrics

513-636-1335

513-636-3549

Board Certified

My Biography & Research

Clinical Interests

Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics.

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Leukemia

Research Divisions

Experimental Hematology and Cancer Biology, Oncology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Utah, Salt Lake City, UT, 2004.

Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 2008; Pediatric Hematology/Oncology, 2011.

My Publications

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. Frontiers in Oncology. 2021; 11.

FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Sheng, Y; Yu, C; Liu, Y; Hu, C; Ma, R; Lu, X; Ji, P; Chen, J; Mizukawa, B; Huang, Y; et al. Nature Communications. 2020; 11.

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. He, X; Dou, A; Feng, S; Roman-Rivera, A; Hawkins, C; Lawley, L; Zhang, J; Wunderlich, M; Mizukawa, B; Halene, S; et al. Experimental Hematology. 2020; 86:21-27.e2.

Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Journal of Clinical Oncology. 2020; 38:e22502-e22502.

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Hayashi, Y; Goyama, S; Liu, X; Tamura, M; Asada, S; Tanaka, Y; Fukuyama, T; Wunderlich, M; O'Brien, E; Mizukawa, B; et al. Nature Communications. 2019; 10.

Improved chemotherapy modeling with RAG-based immune deficient mice. Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. PLoS ONE. 2019; 14.

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Wunderlich, M; Chen, J; O'Brien, E; Manning, N; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Blood. 2019; 134:3766-3766.

The Small Molecule IODVA1 Inhibits the Rac Guanine Nucleotide Exchange Factor Vav3 and Overcomes TKI-Resistance in Ph+(BCR-ABL1) B-ALL. Nassar, N; Hegde, SN; Gasilina, A; Wunderlich, M; Premnauth, G; Merino, E; Lin, Y; Ahmadian, R; Zheng, Y; Mizukawa, B; et al. Blood. 2019; 134:4647-4647.